ArticleInfectious medicine2025
The growing interests in Epstein-Barr virus: A bibliometric analysis of research trends, collaborations, and emerging hotspots.
Article in Infectious medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epstein-Barr Virus (EBV) is a widespread human γ-herpesvirus linked to cancers and autoimmune diseases, but limited comprehensive bibliometric analysis appear to have been conducted in this field. Methods: Using Web of Science data, 16,318 EBV-related documents (2014-2023) were analyzed via VOSviewer, Bibliometrix, and Citespace following the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline. Results: This cross-sectional bibliometric analysis of 16,318 EBV-related documents (2014-2023) revealed a consistent upward trend in annual publications, reflecting growing global interest in EBV research. Collaborative networks demonstrated strong international partnerships, particularly between the United States and China. Keywords co-occurrence and burst analysis highlighted enduring focus on EBV pathogenesis, immune evasion mechanisms, and EBV-associated diseases like nasopharyngeal carcinoma, Hodgkin lymphoma, and multiple sclerosis. On the basis of this comprehensive bibliometric analysis, it showed that the emerging hotspots included immunotherapy, biomarkers, viral reactivation, and vaccine development, with clinical trials evaluating immune-checkpoint inhibitors of toripalimab, mRNA-based therapeutic vaccines targeting LMP2 and EBNA1, and prophylactic strategies such as glycoproteins-based ferritin nanoparticles or mRNA vaccines, indicating a shift toward precision interventions. Conclusions: EBV research has grown exponentially, driven by insights into structural-function relationships and immune evasion. Advances enable targeted prophylactic/therapeutic strategies. The analysis highlights needs to decode virus-host interactions, optimize vaccines, and translate findings clinically, aiming to raise disease awareness, guide immunotherapies, and reduce global health burdens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.